Xenon Pharmaceuticals Inc. · Healthcare · Biotechnology
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$43.26
−$1.67 (−3.71%) 4:00 PM ET
After hours$43.23
−$0.03 (−0.06%) 8:25 AM ET
Prev closePrevC$44.92
OpenOpen$45.20
Day highHigh$46.72
Day lowLow$42.02
VolumeVol1,607,881
Avg volAvgVol812,997
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$3.34B
P/E ratio
-9.92
FY Revenue
$7.50M
EPS
-4.36
Gross Margin
100.00%
Sector
Healthcare
AI report sections
MIXED
XENE
Xenon Pharmaceuticals Inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
+141% (Above avg)
Vol/Avg: 2.41×
RSI
62.93(Strong)
Strong (60–70)
0255075100
MACD momentum
Intraday
+0.00 (Strong)
MACD: 0.04 Signal: 0.03
Short-Term
+0.38 (Strong)
MACD: 0.55 Signal: 0.17
Long-Term
+0.33 (Strong)
MACD: 0.15 Signal: -0.18
Intraday trend score
54.00
LOW47.00HIGH93.50
Latest news
XENE•12 articles•Positive: 4Neutral: 1Negative: 0
NeutralThe Motley Fool• Jonathan Ponciano
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million
Commodore Capital increased its stake in Spyre Therapeutics by 400,161 shares ($10.46 million) in Q4, bringing its total position to $78.24 million (5.21% of AUM). SYRE stock has surged 63% over the past year, significantly outperforming the S&P 500's 13% gain. The preclinical biotech company, focused on inflammatory bowel disease treatments, has a strong balance sheet with $757 million in cash and expects runway into H2 2028, with six Phase 2 readouts expected in 2026.
Mentioned as a comparable holding in Commodore Capital's portfolio (5.4% of AUM, $80.68M) but no specific news or analysis provided in the article.
PositiveGlobeNewswire Inc.• Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals granted 39,250 share options to five new non-officer employees, with options vesting over four years and an exercise price of $44.61 per share.
Company is expanding workforce and providing competitive equity compensation, indicating growth and confidence in future prospects
PositiveGlobeNewswire Inc.• Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals granted 24,200 share options to six new non-officer employees, with an exercise price of $30.54 per share, vesting over four years.
Company is expanding workforce and offering competitive equity compensation, indicating growth and financial stability
PositiveGlobeNewswire Inc.• N/A
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Inc. announced equity inducement grants to four new non-officer employees, consisting of 78,600 share options and 1,800 performance share units. The share options have an exercise price of $38.28 per common share and vest over four years, while the performance share units will vest based on the achievement of certain predefined milestone-based objectives over an approximately three-year period.
XENEXenon Pharmaceuticalsequity inducement grantsshare optionsperformance share units
Sentiment note
The article announces that Xenon Pharmaceuticals is granting equity inducement grants to new employees, which is a positive sign of the company's growth and commitment to attracting and retaining talent.
PositiveGlobeNewswire Inc.• Delveinsight
Epilepsy Market Assessment in the 7MM by 2034 — A Detailed Analysis of Growth Prospects Across Different Types | DelveInsight
The epilepsy market is expected to grow due to an increase in disease prevalence and the launch of emerging therapies. The market is segmented into partial epilepsy, chronic focal epilepsy, and drug-resistant epilepsy, with various treatment options and pipeline drugs.
The article mentions Xenon Pharmaceutical's XEN1101 as one of the emerging therapies expected to launch during the forecast period, indicating a positive outlook for the company.
UnknownZacks Investment Research• Zacks Equity Research
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.
CGENXENEALXOLBPH
UnknownGlobeNewswire Inc.• Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner (XEN1101) clinical data in major depressive disorder (MDD) at the American Society of Clinical Psychopharmacology (ASCP) 2024 Annual Meeting in Miami, FL.
XENECalendar of EventsClinical Study
UnknownZacks Investment Research• Zacks Equity Research
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well.
NBIXANIPXENEANVS
UnknownGlobeNewswire Inc.• Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025
XENEEarnings Releases and Operating Results
UnknownGlobeNewswire Inc.• Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the BofA Securities Health Care Conference 2024 taking place May 14-16, 2024 in Las Vegas, NV.
XENECalendar of EventsConference Calls/ Webcasts
UnknownGlobeNewswire Inc.• Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the 2024 RBC Capital Markets Global Healthcare Conference taking place May 14-15, 2024 in New York, NY.
XENEConference Calls/ Webcasts
UnknownZacks Investment Research• Zacks Equity Research
What Makes Xenon Pharmaceuticals (XENE) a New Buy Stock
Xenon Pharmaceuticals (XENE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
XENE
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
